Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1674220 | 0.78 | SYK (0.39) | SYK | |
| SCHEMBL12636292 | 0.77 | SYK (0.39) | SYK | |
| SCHEMBL29963047 | 0.73 | SYK (0.41) | SYK | |
| SCHEMBL367112 | 0.73 | SYK (0.41) | SYK | |
| SCHEMBL29935925 | 0.73 | SYK (0.36) | SYK | |
| SCHEMBL1674327 | 0.70 | PTK2 (0.44) | SYK | |
| SCHEMBL4047521 | 0.67 | — | — | |
| SCHEMBL18181697 | 0.67 | — | — | |
| SCHEMBL4438858 | 0.67 | — | — | |
| SCHEMBL18181699 | 0.65 | SYK (0.41) | SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022199652-A1 | FIVE-MEMBERED HETEROARYL-PYRIMIDINE COMPOUNDS AS USP1 INHIBITORS AND THE USE THEREOF | IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) | 2022-09-29 | — | — | WO | disclosed |
| EP-3109249-A1 | N-CONTAINING HETEROCYCLIC COMPOUNDS | YM BioSciences Australia Pty Ltd (AU) | 2016-12-28 | — | — | EP | disclosed |
| US-9499560-B2 | N-containing heterocyclic compounds | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2016-11-22 | — | — | US | disclosed |
| US-9499560-B2 | N-containing heterocyclic compounds | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2016-11-22 | — | — | US | disclosed |
| US-9499560-B2 | N-containing heterocyclic compounds | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2016-11-22 | — | — | US | disclosed |
| EP-2215094-B1 | N-CONTAINING HETEROCYCLIC COMPOUNDS | YM BIOSCIENCES AUSTRALIA PTY (AU) | 2016-01-27 | — | — | EP | disclosed |
| US-8765755-B2 | N-containing heterocyclic compounds | YM BIOSCIENCES AUSTRALIA PTY LTD. (AU) | 2014-07-01 | — | — | US | disclosed |
| US-8765755-B2 | N-containing heterocyclic compounds | YM BIOSCIENCES AUSTRALIA PTY LTD. (AU) | 2014-07-01 | — | — | US | disclosed |
| US-8765755-B2 | N-containing heterocyclic compounds | YM BIOSCIENCES AUSTRALIA PTY LTD. (AU) | 2014-07-01 | — | — | US | disclosed |
| US-20130090336-A1 | N-CONTAINING HETEROCYCLIC COMPOUNDS | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2013-04-11 | — | — | US | disclosed |
| CN-102924473-A | Preparation method of 2-chlorine-7-iodothieno[3,2-D] pyrimidine | SHANGHAI BEPHARM CO LTD | 2013-02-13 | — | — | CN | disclosed |
| CN-102924473-A | Preparation method of 2-chlorine-7-iodothieno[3,2-D] pyrimidine | SHANGHAI BEPHARM CO LTD | 2013-02-13 | — | — | CN | disclosed |
| US-8354408-B2 | N-containing heterocyclic compounds | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2013-01-15 | — | — | US | disclosed |
| US-8354408-B2 | N-containing heterocyclic compounds | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2013-01-15 | — | — | US | disclosed |
| US-8354408-B2 | N-containing heterocyclic compounds | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2013-01-15 | — | — | US | disclosed |
| US-20110092499-A1 | N-CONTAINING HETEROCYCLIC COMPOUNDS | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2011-04-21 | — | — | US | disclosed |
| US-20110092499-A1 | N-CONTAINING HETEROCYCLIC COMPOUNDS | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2011-04-21 | — | — | US | disclosed |
| US-20110092499-A1 | N-CONTAINING HETEROCYCLIC COMPOUNDS | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2011-04-21 | — | — | US | disclosed |
| EP-2215094-A1 | N-CONTAINING HETEROCYCLIC COMPOUNDS | YM BioSciences Australia Pty Ltd (AU) | 2010-08-11 | — | — | EP | disclosed |
| WO-2009062258-A1 | N-CONTAINING HETEROCYCLIC COMPOUNDS | CYTOPIA RESEARCH PTY LTD (AU) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090336-A1 | N-CONTAINING HETEROCYCLIC COMPOUNDS | JAK2, JAK3, JAK1 | SYK 138/4885 |
| US-20110092499-A1 | N-CONTAINING HETEROCYCLIC COMPOUNDS | JAK2, JAK3, JAK1 | SYK 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.